National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Research
 Research by Topic
 Research Resources


HIV/AIDS
 Basic Science
 Prevention
 Therapeutics
 Vaccines
  Introduction and Goals
  Research Activities
  Advisory and Working Groups
  Resources for Researchers
  Funding
  Meetings
  Reports and Articles
   National AIDS Vaccine Advocates Forum
  Clinical Trials

 

Cellular Immunity and HIV Vaccines, continued

Another strategy is to destroy the cells that have been infected by the virus. To do this, scientists try to design products that would stimulate the body to produce immune cells called CTLs that will attack and destroy virus-infected cells.
  • Unlike some other viruses, HIV can be transmitted and can exist in the body in two forms: free viruses and virus-infected cells. So, a vaccine against HIV may be required to stimulate both neutralizing antibodies and CTLs.
  • It is difficult to design a single product that can do both, so scientists are also combining two or more different products in order to achieve this goal. Of course, it is also possible that a third immune response is the key to protection against HIV.

previous link Previous Slide | Table Of Contents | Next Slide next link